Table 2.
Response to treatment, OS, PFS and LFS according to the treatment regimen.
| Response | Treatment regimen |
P | ||
|---|---|---|---|---|
| ESA (n = 13) | HMA (n = 19) | |||
| HI-E (n/%) | 9 (69.2 %) | |||
| HI-P (n/%) | 8 (61.5 %) | |||
| HI-N (n/%) | 9 (69.2 %) | |||
| HIs (n/%) | 8 (61.5 %) | |||
| CR (n/%) | 4 (21.1 %) | |||
| PR (n/%) | 5 (26.3 %) | |||
| Marrow CR (n/%) | 1 (5.2 %) | |||
| Survival | ESA (n = 13) | HMA (n = 19) | ||
| OS | Months | 30.44 | 34.27 | P > 0.05 |
| CI 95 % | 26.41–34.47 | 28.47–40.1 | ||
| LFS | Months | 28.91 | 31.45 | P > 0.05 |
| CI 95 % | 23.31–34.51 | 24.69- 38.21 | ||
| PFS | Months | 28.29 | 26.83 | P > 0.05 |
| CI 95 % | 21.83- 34.76 | 20.08- 33.58 | ||
Note: ESA: erythropoietin stimulating agent.
HMA: hypomethylating agent.
HI-E; hematologic improvement erythroid.
HI-P: hematologic improvement platelets.
HI-N: hematologic improvement neutrophils.
HIs: total hematologic improvement (3 lineages).
CR: completed remission.
PR: partial remission.
Marrow CR: marrow completed remission.